RTP Mobile Logo

Interview with Harold J Burstein, MD, PhD

Track 1: Case: A 52-year-old woman with ER/PR-positive, HER2-negative invasive lobular carcinoma receives neoadjuvant endocrine therapy on a clinical trial
Track 2: Role of neoadjuvant therapy for patients with node-positive invasive lobular carcinoma
Track 3: Phase II PELOPS study evaluating neoadjuvant endocrine therapy with or without palbociclib
Track 4: Mechanism of action and efficacy of CDK4/6 inhibitors for ER-positive, HER2-negative metastatic breast cancer (BC)
Track 5: Side effects associated with CDK4/6 inhibitors
Track 6: Efficacy of CDK4/6 inhibitors with endocrine therapy in the neoadjuvant setting
Track 7: Ki-67 proliferation index as a potential surrogate marker for tumor response to endocrine therapy
Track 8: Role of the 21-gene assay Recurrence Score® (RS) in guiding adjuvant therapy decision-making
Track 9: Design and eligibility criteria of the Phase III TAILORx study of adjuvant chemoendocrine therapy versus endocrine therapy for patients with ER-positive, HER2-negative, node-negative BC and an intermediate RS
Track 10: Rationale for and clinical implications of the TAILORx study
Track 11: Perspective on the clinical relevance of genomic assays for patients with node-positive BC
Track 12: Importance of the results of the TAILORx study for women with ER-positive, HER2-negative BC
Track 13: Choice of endocrine therapy for premenopausal women with ER-positive, HER2-negative BC
Track 14: Determinants of adherence to adjuvant endocrine therapy
Track 15: Approaches to alleviate arthralgias associated with aromatase inhibitors
Track 16: Fertility preservation and pregnancy issues for patients with BC
Track 17: Counseling women about pregnancy after BC
Track 18: Emerging data on the efficacy of immune checkpoint inhibitors in patients with metastatic triple-negative BC
Track 19: Case: A 49-year-old woman with a 6-cm, ER-positive, HER2-positive tumor and a palpable axillary lymph node achieves a pathologic complete response to neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP)
Track 20: Activity and tolerability of HER2-targeted therapy

Interview with Terry Mamounas, MD, MPH

Track 1: Case: A 58-year-old woman with ER/PR-positive, HER2-negative invasive ductal carcinoma and a RS of 25 receives adjuvant chemotherapy and an aromatase inhibitor
Track 2: Role of adjuvant chemotherapy for patients with ER-positive, HER2-negative, node-negative BC and an intermediate RS
Track 3: TAILORx results: Adjuvant chemotherapy guided by the 21-gene assay RS for patients with ER-positive, HER2-negative, node-negative BC
Track 4: Viewpoint on the clinical utility of the 21-gene assay RS
Track 5: Comparison of the 21-gene and 70-gene assays
Track 6: Use of the 21-gene assay for patients with node-positive disease
Track 7: Case registry analysis of clinical outcomes of patients with ER-positive, HER2-negative, node-positive BC treated according to their 21-gene assay RS
Track 8: Overview of radiation therapy techniques
Track 9: Case: A 56-year-old woman with a 1.2-cm ductal carcinoma in situ (DCIS) and a DCIS ScoreTM of 20
Track 10: Consensus guidelines on margins for breast-conserving surgery for patients with DCIS
Track 11: Case: A 38-year-old woman with a BRCA1 germline mutation and a family history of breast and peritoneal cancer undergoes prophylactic bilateral nipple-sparing mastectomy
Track 12: Optimal timing of sentinel lymph node biopsy for patients receiving neoadjuvant chemotherapy
Track 13: Management of the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy
Track 14: Monitoring the axilla in patients with early-stage BC not treated with neoadjuvant chemotherapy
Track 15: Long-term outcomes with neoadjuvant versus adjuvant chemotherapy in early-stage BC
Track 16: Role of the 21-gene assay RS in guiding neoadjuvant chemotherapy decision-making
Track 17: Final analysis of the CALOR trial evaluating the efficacy of chemotherapy for isolated locoregional recurrence of BC
Track 18: Case: A 67-year-old woman with ER/PR-positive, HER2-positive BC achieves a complete clinical and radiologic response to neoadjuvant TCHP
Track 19: Perspective on the use of (neo)adjuvant pertuzumab
Track 20: Overview of ongoing NSABP clinical trials in the neoadjuvant and adjuvant settings
Harold J Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Terry Mamounas, MD, MPH
Medical Director, Comprehensive Breast Program
Orlando Health UF Health Cancer Center
Professor of Surgery
University of Central Florida
Orlando, Florida
Neil Love, MD
Research To Practice
Miami, Florida